-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
GP(33-41)TFA
Category | Arenavirus |
Description | GP(33-41) TFA, a 9-aa-long peptide, is the optimal sequence of the GP1 epitope of lymphocytic choriomeningitis virus |
Product Information
Molecular Weight | 1130.19 |
Molecular Formula | C48H70F3N110O15S |
Purity | 99.70% |
Solubility | In Vitro: H2O : 1.82 mg/mL(1.61 mM;ultrasonic and adjust pH to 4 with HCl) |
Appearance | White to off-white (Solid) |
Storage | Sealed storage, away from moisture and light Powder -80°C 2 years -20°C 1 years * In solvent -80°C 6 months -20°C 1 month (sealed storage, away from moisture and light) |
In Vitro | GP(33-41) TFA sensitizes MC57 and T2-Db cells to lysis with ED50s of 0.9±0.6 and 2.5±0.7 nM. The interaction between T cell receptors (TCR) and peptide-major histocompatibility complex (pMHC) antigens can lead to varying degrees of agonism (T cell activation), or antagonism. The P14 TCR recognises the lymphocytic choriomeningitis virus (LCMV)-derived peptide, GP(33-41) (KAVYNFATC), presents in the context of H-2D. |
PSA | 20.23000 |
Target | Arenavirus |